Clinical Trial: A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053020) titled 'A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)' on June 30.

Brief Summary: The goal of Part 1 of this clinical research study is to find the highest tolerable dose of cladribine that can be given in combination with low dose cytarabine (LDAC) and venetoclax to patients who have AML.

The goal of Part 2 of this clinical research study is to learn if the dose of cladribine found in Part 1, when combined with LDAC and venetoclax, can help to control the disease.

Study Start Date: Dec. 01, 2025

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemi...